Non-contact Vital Signs Monitoring in Paediatric Anaesthesia - Current Challenges and Future Direction.

Non-contact vital sign monitoring is an area of increasing interest in the clinical scenario since it offers advantages over traditional monitoring using leads and wires. These advantages include reduction in transmission of infection and more freedom of movement. Yet there is a paucity of studies available in the clinical setting particularly in paediatric anaesthesia. This scoping review aims to investigate why contactless monitoring, specifically with red-green-blue cameras, is not implemented in mainstream practise. The challenges, drawbacks and limitations of non-contact vital sign monitoring, will be outlined, together with future direction on how it can potentially be implemented in the setting of paediatric anaesthesia, and in the critical care scenario.

Status of the Sentinel Lymph Node in Patients with Endometrial Cancer Stage I-II.

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. In literature, there are discordant data regarding the therapeutic value of systematic lymphadenectomy whereas the importance of lymph node status for determining prognosis and the need for adjuvant treatment is undoubted. Given the low risk of lymph node metastases in stage I-II of EC and the significant surgical and postoperative risks when performing a complete pelvic lymphadenectomy, the surgical approach in these patients is controversial, ranging from no nodal evaluation to comprehensive pelvic and aortic lymphadenectomy. The recent introduction of sentinel node detection represents the mid-way between the execution and omission of node dissection in EC patients. Indeed, the sentinel node mapping has rapidly emerged as an alternative to complete lymphadenectomy to reduce morbidity. In the present research, we discuss the role of sentinel node mapping in the surgical management of EC in early stage. Results of study on SLN in EC in early stages seem to be promising, but only a small series have been published so far.

Steroids-has the time come to extend their use to AML?

BACKGROUND: In 2018, leukaemia accounted for 2.6% of all new cancers, it being the 13th most common cause of cancer and the 10th most common cause of cancer death. Glucocorticoids are commonly used in lymphoid leukaemia treatment, where they are cytotoxic. The aim of this review is to highlight ongoing research of steroid use in myeloid leukaemias. MAIN TEXT: Glucocorticoids increase infection risks in acute myeloid leukaemia, but with adequate antifungal cover, they can help in hyperleucocytic disease. They also show some benefits in sensitising multidrug-resistant AML cell lines to cytotoxic agents, induce differentiation marker expression and can also induce CD38 expression, making AML cells possible targets of daratumumab. Cardiotonic steroids, like digitalis, are being recognised as sensitising AML cells to the chemotherapeutic effects of many cytotoxic agents, primarily by inhibiting efflux pumps, thus minimising AML resistance. Ecdysteroids enhance sensitivity in multidrug-resistant AML, but also in non-resistant AML cell lines, through pathways including the activation of mitochondrial apoptosis. Their anti-apoptotic effects on non-malignant cell lines help their target specificity. Sensitisation is chemotherapy-specific, enhancing the effects of doxorubicin and tubulin inhibitors but increasing resistance to cisplatinum. SHORT CONCLUSION: Cardiotonic steroids and ecdysteroids both show chemosensitisation to the cytotoxic effects of chemotherapy on AML cell lines. It is likely time to consider clinical trials to assess whether these, as well as traditional glucocorticoids, can contribute to the AML armamentarium, particularly in chemo-resistant disease.

Therapeutic Potential of Ecdysteroids and Steroidal Alkaloids on Solid Cancers.

BACKGROUND: Cancer is the second most common cause of death globally. Common modalities of treatment include surgery, chemotherapy, radiotherapy and lately immunotherapy. Different steroidal agents have also been identified as therapeutics for solid cancers, often as part of chemotherapy regimens. This review will specifically focus on steroidal alkaloids and ecdysteroids, which are different types of steroids originating from plants and arthropods respectively. These have been proven to show anti-cancer effects through several methods, including inhibition of proliferation and increasing apoptosis in cancer cells. Synthetic steroids are also used as chemotherapy adjuvants. By increasing our knowledge and understanding of these compounds, further studies can be carried out which may lead to clinical trials. This may enable a potential alternative to current therapies used as cancer treatment today, and may help improve the standard of care.